Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CEO Lindsay Md Rosenwald bought 54,776 shares of Fortress Biotech stock in a transaction dated Wednesday, November 18th. The shares were bought at an average cost of $1.90 per share, with a total value of $104,074.40. Following the completion of the transaction, the chief executive officer directly owned 4,706,108 shares in the company, valued at approximately $8,941,605.20. This trade represents a 1.18% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Fortress Biotech Trading Down 5.7%
NASDAQ:FBIO opened at $1.78 on Friday. Fortress Biotech, Inc. has a 12 month low of $1.64 and a 12 month high of $4.53. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10. The firm’s 50 day moving average is $2.07 and its 200 day moving average is $2.69. The stock has a market capitalization of $60.16 million, a PE ratio of 0.78 and a beta of 1.27.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last released its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.04. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $21.57 million. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. Sell-side analysts expect that Fortress Biotech, Inc. will post 2.66 earnings per share for the current year.
Fortress Biotech News Roundup
Investors following FBIO have been watching these news items:
- Positive Sentiment: CEO Lindsay Rosenwald and CFO David Jin bought a combined 184,328 shares in transactions from November 17–19, investing about $340,000. The purchases increased both executives’ holdings and may signal confidence in the company, though insider buying alone does not establish a change in business outlook. CEO filing CFO filing
- Neutral Sentiment: Zacks initiated coverage with a “hold” rating, offering no clear bullish or bearish signal. Zacks ratings
- Neutral Sentiment: HC Wainwright estimates earnings per share of $2.66 for FY2026, in line with consensus, and $2.37 for FY2027. The lower projected figure for 2027 may temper optimism, but these are analyst estimates rather than company guidance. HC Wainwright estimate coverage
Institutional Investors Weigh In On Fortress Biotech
Several institutional investors have recently made changes to their positions in FBIO. Squarepoint Ops LLC bought a new position in shares of Fortress Biotech in the second quarter worth $47,000. Renaissance Technologies LLC grew its position in shares of Fortress Biotech by 22.8% in the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 18,490 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Fortress Biotech during the 3rd quarter valued at $462,000. Hedge funds and other institutional investors own 96.51% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the company. Wall Street Zen cut Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research began coverage on shares of Fortress Biotech in a research report on Wednesday. They set a “hold” rating for the company. Finally, Weiss Ratings lowered shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Fortress Biotech presently has a consensus rating of “Hold” and a consensus target price of $17.00.
View Our Latest Stock Report on FBIO
About Fortress Biotech
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Further Reading
- Five stocks we like better than Fortress Biotech
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
